Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceResearch Article Published on 2021-01-152024-09-02 Journal: BMC Cancer [Category] 대상포진, [키워드] clinical trial Dexamethasone Ixazomib lenalidomide Multiple myeloma Patient registry [DOI] 10.1186/s12885-020-07732-1 PMC 바로가기 [Article Type] Research Article
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myelomaReview Article Published on 2020-04-162024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] adverse events lenalidomide Multiple myeloma Newly diagnosed Safety [DOI] 10.1007/s00277-020-04023-4 PMC 바로가기 [Article Type] Review Article
Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or BortezomibResearch Article Published on 2019-12-182024-09-02 Journal: Turkish Journal of Hematology [Category] 대상포진, [키워드] antiviral therapy bortezomib Hepatitis B reactivation lenalidomide Multiple myeloma [DOI] 10.4274/tjh.galenos.2019.2019.0103 PMC 바로가기 [Article Type] Research Article
The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cellsOriginal Research Published on 2019-07-122024-09-04 Journal: Journal of Blood Medicine [Category] 대상포진, [키워드] IMIDs lenalidomide Multiple myeloma plasmacyotid DCs type I IFNs [DOI] 10.2147/JBM.S206459 PMC 바로가기 [Article Type] Original Research
Low frequency of CD3 + CD4 + CD161 + T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatmentOriginal Article Published on 2018-06-252024-09-04 Journal: Annals of Hematology [Category] 대상포진, [키워드] Infection lenalidomide Low-dose dexamethasone Multiple myeloma [DOI] 10.1007/s00277-018-3401-y PMC 바로가기 [Article Type] Original Article
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myelomaOriginal Research Published on 2018-04-192024-09-02 Journal: Cancer Medicine [Category] 대상포진, [키워드] clinical trial lenalidomide Multiple myeloma [DOI] 10.1002/cam4.1422 PMC 바로가기 [Article Type] Original Research
A Brighter Side to Thalidomide: Its Potential Use in Immunological Disordersarticle Published on 2017-04-302024-09-01 Journal: Trends in molecular medicine [Category] 한센병, [키워드] cereblon IMID lenalidomide thalidomide [Article Type] article
Total cost comparison in relapsed/refractory multiple myelomaArticle Published on 2013-09-252024-09-04 Journal: Journal of medical economics [Category] 대상포진, [키워드] bortezomib cost of care lenalidomide Myeloma relapsed/refractory multiple myeloma [DOI] 10.3111/13696998.2012.760159 PMC 바로가기 [Article Type] Article
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaArticle Published on 2013-05-272024-09-04 Journal: International journal of hematology [Category] 대상포진, [키워드] elderly lenalidomide Multiple myeloma refractory Relapsed [DOI] 10.1007/s12185-012-1125-7 PMC 바로가기 [Article Type] Article
The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance TreatmentEconomics of Oncology Practice Published on 2013-01-082024-09-04 Journal: The oncologist [Category] 대상포진, [키워드] bortezomib cost-effectiveness lenalidomide Multiple myeloma thalidomide [DOI] 10.1634/theoncologist.2011-0380 PMC 바로가기 [Article Type] Economics of Oncology Practice